{"id":181205,"date":"2025-09-04T20:26:39","date_gmt":"2025-09-04T18:26:39","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=181205"},"modified":"2025-09-09T01:00:33","modified_gmt":"2025-09-08T23:00:33","slug":"rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/","title":{"rendered":"Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform"},"content":{"rendered":"<div>\n<p>Statement issued by the company (Announcement)<\/p>\n<p><strong>Rapafusyn Pharmaceuticals<\/strong>, a leader in the discovery and development of<strong> non-degrading molecular glue<\/strong> therapeutics, today announced the closing of its over-subscribed Series A financing round with the addition of investors BioTrack Capital and Yonjin Capital. Total funds raised in the Series A round are $44 million, which includes $24 million committed previously. <strong>BioTrack Capital <\/strong>and <strong>Yonjin Capital<\/strong> join other distinguished investors in the Series A including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital.<\/p>\n<p>Rapafusyn was co-founded by Professor Jun O. Liu of Johns Hopkins University School of Medicine, a pioneer in the molecular glue field, with initial funding support from <strong>Jiangsu Tianqin Investment Ltd<\/strong>.<\/p>\n<p>The financing accelerates the advancement of Rapafusyn\u2019s broad drug pipeline addressing many diseases of high unmet medical need in the oncology, immunology, renal and pain disease areas by leveraging RapaGlues\u2122 \u2014 a groundbreaking non-degrading molecular platform that can access challenging or previously undruggable disease targets.<\/p>\n<p>The RapaGlue\u2122 platform\u00a0has demonstrated the ability to create highly cooperative non-degrading molecular glues with high cell membrane permeability to modulate protein\u2013protein interactions, transcription factors, SLCs\/transporters, ion channels, enzymes,\u00a0and others. Rapafusyn applies innovative machine learning (ML)\/AI methods as an integral part of target selection and drug candidate optimization that result in an industry leading success rate at discovering relevant chemical matter for hard-to-drug targets. Rapafusyn\u2019s lead program, a selective ENT1 inhibitor, is advancing toward IND-enabling studies after showing compelling activity in renal disease models \u2014 a powerful validation of the RapaGlue\u2122 platform\u2019s therapeutic potential. Rapafusyn is also leveraging its DNA-encoded library of more than 8 billion non-degrading molecular\u00a0glues in a collaboration with a global pharmaceutical partner.<\/p>\n<p>&#8220;With the successful closing of our Series A financing, we are positioned to propel the RapaGlue\u2122 platform and to accelerate our mission to deliver transformative therapies to patients in need,&#8221; Dr. Sean Hu, President and CEO of Rapafusyn, commented. \u201cWe are pleased to have BioTrack Capital and Yonjin Capital join this financing round.\u201d<\/p>\n<p>\u201cRapafusyn and the RapaGlue\u2122 platform are rewriting what\u2019s possible in drug discovery with a new class of macrocyclic molecules,\u201d said Dr. Karen Liu, a Founding Partner at 3E Bioventures. \u201cI am excited about the platform\u2019s ability to expand beyond traditional small molecules and recent degrader molecules to approach previously undruggable targets.\u201d<\/p>\n<p>Existing investors Haolin Sung, Partner of Proxima Ventures and Jian Li, Partner of Lapam Capital, each expressed enthusiasm for the new financing and looked forward to joining forces with the new investors as Rapafusyn accelerates its platform and pipeline development.<\/p>\n<p>Kai Chen, Vice President of BioTrack Capital commented, \u201cWe are thrilled to invest in Rapafusyn for the potential of their innovative non-degrading molecular glue platform. It stands out as a highly differentiated drug modality for previously undruggable disease targets which hold substantial promise for diseases with unmet need.\u201d<\/p>\n<p>Wen Chen, Partner at Yonjin Capital added, \u201cThe Rapafusyn team has made remarkable progress in discovering high potential drug candidates using their RapaGlue\u2122 platform. We are also very impressed by Rapafusyn\u2019s operating and advisory teams and are delighted to join the Series A round.\u201d<\/p>\n<h2><strong>About BioTrack Capital<\/strong><\/h2>\n<p>Established in 2017, BioTrack is a venture capital firm that focuses on investing in and incubating outstanding early-stage biotech, medtech as well as healthcare cross disciplinary sectors (AI and digital healthcare, consumer healthcare, etc). The BioTrack professional investment team possess strong and complementary skills in research and development, clinical operations, consulting, and investment.<\/p>\n<h2><strong>About Yonjin Capital<\/strong><\/h2>\n<p>Yonjin Capital is a leading international investment firm that specializes in early- and mid-stage life science companies in therapeutics, diagnostics and medical devices. The Yonjin Capital team has broad global knowledge, in-depth experience, and extensive networks which enable their portfolio companies to achieve remarkable results. Yonjin Capital is the North America and Europe investment arm of Yonjin Group and the sister firm of Yonghua Capital, both based in China with headquarters in Shanghai.<\/p>\n<h2><strong>About Rapafusyn Pharmaceuticals<\/strong><\/h2>\n<p>Rapafusyn emerged from the laboratory of Dr. Jun O. Liu\u2019s, Professor of Pharmacology and Molecular Sciences at Johns Hopkins University, with a mission to develop transformational medicines to address high unmet medical needs and enhance patient care.\u00a0 The platform leverages non-degrading macrocyclic molecular glues (RapaGlues<sup>\u2122<\/sup>) to address challenging therapeutic targets.\u00a0 Rapafusyn has constructed both DNA-encoded libraries (DELs) and arrayed libraries of RapaGlues\u2122 that form neo-PPIs to inhibit a protein from its native activity. These compounds are rationally designed and engineered to bind FKBP and form a ternary complex with the disease target protein, offering a promising avenue for modulating intricate protein-protein interactions.\u00a0 RapaGlues\u2122 have proven effective in producing innovative chemical starting points for challenging drug targets.\u00a0 The modular architecture enables SAR and subsequent optimization for potency, selectivity, and physicochemical properties to accelerate drug discovery and development. RapaGlues\u2122 frequently exhibit cell permeability directly from the starting point, enhancing their potential for therapeutic development.<\/p>\n<pre>For more information, please visit rapafusyn.com \r\nor contact Heather Lavin: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aoktD1J4rQwakPQ3luy40I0OnSi5FaqvX47Xc5ULNeg45MIvFdAJb9hXwUkAVkCwFuRbrWUsIpiORCN0oxiiux8lg1t7HqFTAEcCQqsA3dI=\" target=\"_blank\" rel=\"noopener\">hlavin@rapafusyn.com<\/a><\/pre>\n<p><img \/><em>AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Statement issued by the company (Announcement) Rapafusyn Pharmaceuticals, a leader in the discovery and development of non-degrading molecular glue therapeutics, today announced the closing of its over-subscribed Series A financing [&hellip;]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[125518],"tags":[],"class_list":["post-181205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rapafusyn Pharmaceuticals Closes $44 Million Series<\/title>\n<meta name=\"description\" content=\"Rapafusyn Pharmaceuticals announced the closing of its over-subscribed Series A financing round with BioTrack Capital and Yonjin Capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rapafusyn Pharmaceuticals Closes $44 Million Series","description":"Rapafusyn Pharmaceuticals announced the closing of its over-subscribed Series A financing round with BioTrack Capital and Yonjin Capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform","datePublished":"2025-09-04T18:26:39+00:00","dateModified":"2025-09-08T23:00:33+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/"},"wordCount":889,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/","url":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/","name":"Rapafusyn Pharmaceuticals Closes $44 Million Series","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2025-09-04T18:26:39+00:00","dateModified":"2025-09-08T23:00:33+00:00","description":"Rapafusyn Pharmaceuticals announced the closing of its over-subscribed Series A financing round with BioTrack Capital and Yonjin Capital.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/rapafusyn-pharmaceuticals-closes-over-subscribed-44-million-series-a-financing-to-advance-its-non-degrading-molecular-glue-drug-discovery-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-L8F","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/181205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=181205"}],"version-history":[{"count":4,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/181205\/revisions"}],"predecessor-version":[{"id":181855,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/181205\/revisions\/181855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=181205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=181205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=181205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}